Pharmacotherapy of dementia with Lewy bodies

Bibliography

• LEWY FH: Paralysis agitans.I. Pathologische Anatomie. In: Han dbuch der Neurologie (Vol. 3/II). Lewandowsky M (Ed.), Julius Springer, Berlin, Germany (1912):920–933.
   Google Scholar
• LEWY FH: Die lehre vom tonus und der bewegung. Springer-Verlag, Berlin, Gremany (1923).
   Google Scholar
• HASSLER R: Zur pathologie der paralysis agitans und des postencephalitischen parkinsonismus. I Pasyhcol. Neurology (1938) 48:387–476.
   Google Scholar
• WOODWARD JS: Concentric hyaline inclusion body formation in mental disease. Analysis of twenty-seven cases. Neuropathol Exp. Neurol (1962) 21:442–449.
   PubMedGoogle Scholar
• BYRNE EJ, LENNOX G, LOWE J, GOD WIN-AUSTENRB: Diffuse Lewy bodiy disease: clinical features in 15 cases. Neura Neurosurgery Psychiatry (1989) 52:709–717.
   PubMed Web of Science ®Google Scholar
• LENNOX G, LOWE J, LANDON M, BYRNE EJ, MAYER RJ,GOD WIN-AUSTENRB: Diffuse Lewy body disease: corelative neuropathology using anti-ubiquitin immunocytochemistry.NeuroL Neurosurgery Psychiatry (1989) 52:1236–1247.
   PubMed Web of Science ®Google Scholar
• KOSAKA K: Diffuse Lewy body disease in Japab. Neurol (1990) 237:197–204.
   Google Scholar
• PERRY RH, IRVING D, BLESSED G, FAIRBAIRN A, PERRY EK: Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly.Neurol Sri. (1990) 95:119–139.
   Google Scholar
• DITTER SM, MIRRA SS:Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology (1987) 29:1209–1214.
   Google Scholar
• HANSEN L, SALMON D, GALASKO D et al.: The Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology (1990) 40:1–8.
   PubMed Web of Science ®Google Scholar
• PERRY RH, IRVING D, BLESSED G, FAIRBAIRN A, PERRY EK: Clinically and
   Google Scholar
• ••pathologically distinct form of dementia in the elderly. Lancet (1989) 1:166.
   Google Scholar
• DICKSON DW, RUAN D, CRYSTAL H et al.: Hippocampal degeneration differentiates diffuse Lewy body disease from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurties specific to DLBD. Neurology (1991) 41:1402–1409.
   PubMed Web of Science ®Google Scholar
• MCKEITH IG, GALASKO D,KOSAKA K et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 47:1113–1124.
   Google Scholar
• ••An important paper describing the clinicalcharacteristics of DLB as a distinct clinical syndrome.
   Google Scholar
• LITVAN I, MACINTYRE A, GOETZ CG et al.: Accuracy of the clinical diagnoses of Lewy body disease Parkinson's disease and dementia with lewy bodies. Arch Neurol (1998) 55:969–978.
   PubMed Web of Science ®Google Scholar
• LOPEZ OL, LITVAN I, CATT KE et al: Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementia. Neurology (1999) 53:1292–1299.
   PubMed Web of Science ®Google Scholar
• MEGA MS, MASTERMAN DL, BENSON OF et al.: Dementia with Lewy bodies: reliability and validity of clinical and pathologic crietria. Neurology (1996) 47:1403–1409.
   PubMedGoogle Scholar
• MCKEITH IG, FAIRBAIRN AF, BOTHWELL RA et al: An evaluation of the predictive validity and inter-rater reliability of clinical diagnositic criteria for senile dementia of the Lewy body type. Neurology (1994) 44:872–877.
   PubMed Web of Science ®Google Scholar
• DICKSON DW: Dementia with Lewy bodies: Neuropathology. J. Ceriain Psychiatry Nemo]. (2002) 15:210–216.
   PubMed Web of Science ®Google Scholar
• ••A good review of the neuropathology ofDLB.
   Google Scholar
• KAPLAN B, RATNER V, HAAS E: a-synuclein - its biological function and role in neurodegenerative diseases.J. Molecular Neuroscience (2003) 20:83–92.
   PubMed Web of Science ®Google Scholar
• INCE PG, PERRY EK, MORRIS CM: Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome. Brain Pathol (1998) 8:299–324.
   Google Scholar
• BRAAK H, DEL TREDICI K, RUB U, DE VOS RA, JANSEN STEUR EN, BRAAK E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2003) 24(2):197–211.
   PubMed Web of Science ®Google Scholar
• APAYDIN H, AHLSKOG JE, PARISI JE,BOEVE BE DICKSON DW: Parkinson's disease neuropathology: later developing dementia and loss of the levodopa response. Arch Neurol (2003) 60:452–453.
   Google Scholar
• GEULA C, MESULAM MM,SAROFF DM, WU C-K: Relationship between plaques, tangles and loss of cortical cholinergic fibers in Alzheimer's disease.Neuropathol Exp. Neurol (1998) 57(1):63–75.
   Google Scholar
• LANGLAIS PJ, THAL L, HANSEN L, GALASKO D, ALFORD M, MASLIAH E: Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology (1993) 43:1927–1934.
   PubMedGoogle Scholar
• SHIMOMURA T, MORI E,YAMASHITA H et al.: Cognitive loss in dementia with Lewy bodies and Alzheimer's disease. Arch Neurol (1998) 55:1547–1552.
   Google Scholar
• WALKER MP, AYRE GA,CUMMINGS JL et al.: Quantifying fluctuations in dementia associated with Lewy bodies Alzheimer's disease, and vascular dementia. Neurology (2000) 54:1616–1624.
   Google Scholar
• BALLARD C, HOLMES C, MCKEITH I et al.: Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am. J. Psychiatry (1999) 156(7):1039–1045.
   PubMed Web of Science ®Google Scholar
• MARANTZ AG, VERGHESE J: Capgras'syndrome in dementia with Lewy bodies. Certain Psychiatry Nemo]. (2002) 15:239–241.
   Google Scholar
• BALLARD CG, O'BRIEN J, LOWERY K et al.: A prospective study of dementia with Lewy bodies. Age. Ageing (1998) 27(5):631–66.
   Google Scholar
• BALLARD CG, O'BRIEN JT, SWANN AG et al.: The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease. I. Clin. Psychiatry (2001) 62(1):46–49.
   Google Scholar
• TURNER RS: Idiopathic rapid eye movement sleep behavior disorder is a harbinger of dementia with Lewy bodies. Certain Psychiatry Nemo]. (2002) 15:195–199.
   Google Scholar
• BURKHARDT CR, FILLEY CM, KLEINSCHMIDT-DEMASTERS BK et al.: Diffuse Lewy body disease: clinical features in 15 cases. J. Neurol Neurosurgery and Psychiatry (1989) 52:709–717.
   PubMedGoogle Scholar
• GIBB WRG, LUTHERT PJ, JANOTA I,LANTOS PL: Cortical Lewy Body dementia: clinical features and classification. NeuroL Neurosurgery Psychiatry (1989) 52:185–192.
   PubMedGoogle Scholar
• MCKEITH IG, PERRY RH,FAIRBAIRN AF, JABEEN S, PERRY EK: Operational criteria for senile dementia of Lewy body type. Psycho]. Med. (1992) 22:911–922.
   PubMed Web of Science ®Google Scholar
• GALASKO D, KATZMAN R,SALMON DP: Clinical andneuropathological findings in Lewy body dementia. Brain Cog. (1996) 31:176–185.
   PubMedGoogle Scholar
• AARSLAND D, BALLARD C, MCKEITH I, PERRY RH, LARSEN JP: Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. j. Neuropsychiatry Clin. Neurosci. (2001) 13:374–379.
   PubMedGoogle Scholar
• LOUIS ED, KLATKA LA, LIU Y, FAHN S: Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy bodies and 34 pathologically confirmed cases of Parkinson's disease. Neurology(1997) 48:376–380.
   PubMed Web of Science ®Google Scholar
• RAJPUT AH, ROZDILSKY B: Dysautonomia in parkinsonism: a clinicopathological study. Neurol Neurosurg. Psychiatry (1976) 39:1092–1100.
   PubMed Web of Science ®Google Scholar
• EMILE J, POUPLARD A,BOSSU VAN NIEUWENHUYSE C, BERNAT-VIALLET C: Maladie de Parkinson, dysautonomie at autoanticorps dirges contre les nourones sympathiques. Rev. Neurol (Paris) (1980) 136:123–133.
   Google Scholar
• LANGSTON JW, FORNO LS: The hypothalamus in Parkinson's disease. Ann. Neurol (1978) 3(2):129–133.
   PubMedGoogle Scholar
• BREVETTI G, BONADUCE D et al: Parkinson's disease and hypotension: a 24-hour blood proessure recording in ambulant patients. Clin. Cardiol (1990) 13:474–478.
   PubMedGoogle Scholar
• EDWARDS LL, PFEIFFER RE QUIGLEY EM HOFMAN R,BALLUFF M: Gastrointestinal symptoms in Parkinson's disease. Mov. Disord. (1991) 6:151–156.
   PubMed Web of Science ®Google Scholar
• VAN DIJK JG, HAAN J, ZWINDERMAN K, KREMER B,VAN HILTEN BJ, ROOS RA: Autonomic nervous system dysfunction in Parkinson's disease: relationship with age, medication, duration and severity. J. Neurol Neurosurg. Psychiatry (1993) 56:1090–1095.
   PubMedGoogle Scholar
• KUPSKY WJ, GRIMES MM,SWEETING J, BERTSCH R, COTE LJ: Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology (1987) 37:1253–1255.
   PubMed Web of Science ®Google Scholar
• QUALMAN SJ, HAUPT HM, YANG P, HAMILTON SR: Esophageal lewy bodies associated with ganglion cell less in achalasia. Similarity to Parkinson's disease. Gastroenterology (1984) 87:848–856.
   Google Scholar
• DICKSON DW, DAVIES P, MAYEUX R et al.: Diffuse Lewy body disease: neuropathologic and biochemical studies of six patients. Acta Neuropathol. (1987) 75:8–15.
   PubMed Web of Science ®Google Scholar
• PERRY EK, HAROUTUNIAN V, DAVIS KL et al.: Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuro. Report (1994) 5:747–749.
   PubMed Web of Science ®Google Scholar
• FARLOW M, GRACON SI,HERSHEY LA, LEWIS KW,SAD OWSKY CH, DOLAN-URENO J: A controlled trial of tacrine in Alzheimer'sdisease. JAMA (1992) 268:2523–2529.
   PubMed Web of Science ®Google Scholar
• KNAPP MJ, KNOPMAN DS, SOLOMON PR, PENDLEBURY WW, DAVIS CS, GRACON SI: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JA/VIA (1994) 271:985–991.
   Google Scholar
• ROGERS SL, FARLOW MR,DOODY RS, MOHS R, FRIEDHOFF LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology(1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• BURNS A, ROSSOR M, HECKER J et aL:The effect of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Ceriatr. Cogn. Disord. (1999) 10:237–244.
   PubMed Web of Science ®Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. Br. Med. J. (1999) 318:633–640.
   PubMed Web of Science ®Google Scholar
• COREY-BLOOM J, ANAND R, VEACH J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderatele severe Alzheimer's disease. Int. J. Ceriatr. Psychopharm. (1998) 1:55–65.
   Google Scholar
• TARIOT PN, SOLOMON PR, MORRIS JC, KERSHAW P, LILIENFELD S, DING C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology (2000) 54:2269–2276.
   PubMed Web of Science ®Google Scholar
• RASKIND MA, PESKIND ER, WESSEL T,YUAN W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology (2000) 54:2261–2268.
   PubMed Web of Science ®Google Scholar
• ROSEN WG, MOHS RC, DAVIS KL: A new rating scale for Alzheimer's disease. Am.j Psychiatry (1984) 141:1356–1364.
   PubMed Web of Science ®Google Scholar
• LEVY R, EAGGER S, GRIFFITHS M et al: Lewy bodies and response to tacrine in Alzheimer's disease (letter).Lancet (1994) 343:176.
   PubMedGoogle Scholar
• ROJAS-FERNANDEZ CH: Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann. Pharmacotherapy (2001) 35:202–205.
   PubMedGoogle Scholar
• SHEA C, MACKNIGHT C,ROCKWOOD K: Donepezil for treatment of dementia with Lewy bodies: a case series of none patients. Int. Psychogariati: (1998) 10:229–238.
   PubMedGoogle Scholar
• AARSLAND D, BRONNICK K, KARLSEN K: Donepezil for dementia with Lewy bodies: a case study (letter). Int. Ceriatr. Psychiatry (1999) 14:69–72.
   PubMed Web of Science ®Google Scholar
• KAUFER DI, CATT KE, LOPEZ OL, DEKOSKY ST: Dementia with Lewy bodies: response of delirium-like features to donepezil (letter). Neurology (1998) 51:1512.
   PubMed Web of Science ®Google Scholar
• LANCTOT KL, HERRMANN N: Donepezil for behavioral disorders associated with Lewy bodies: a case series. Int. .1. Ceriatr. Psychiatry (2000) 15:338–345.
   PubMed Web of Science ®Google Scholar
• MCKEITH I, DEL SER T, SPANO PF et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled International study. Lancet (2000) 356:2031–2036.
   PubMed Web of Science ®Google Scholar
• ••The first well-designed, placebo-controlled,large trial on DLB.
   Google Scholar
• WESNES KA, MCKEITH IG, FERRARA R et al.: Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomized placebo-controlled international study using the cognitive drug research computerized assessment system. Dement. Ceriatc Cogn. Disord. (2001) 13:183–192.
   Google Scholar
• SAMUEL W, CALIGIURI M, GALASKO D et al.: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study. Int. I Ceriatr. Psychiatry (2000) 15:794–802.
   PubMed Web of Science ®Google Scholar
• GRACE J, DANIEL S, STEVENS T et al.: Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int. Psychogeriatrics (2001) 13(2):199–205.
   PubMed Web of Science ®Google Scholar
• AARSLAND D, LAAKE K, LARSEN JO, JANVIN C: Donepezil for cognitive impairment in Parkins's disease: a randomized controlled study. Neurol. Neurosurg. Psychiatry (2002) 72:708–712.
   PubMed Web of Science ®Google Scholar
• KAUFER DI: Pharmacologic therapy of dementia with Lewy bodies. j Ceriatr. Psychiatry Neurol. (2002) 15:224–232.
   PubMed Web of Science ®Google Scholar
• ••A useful overview of the presentpharmacotherapy for the treatment of DLB.
   Google Scholar
• DEVANAND DP, MARDER K, MICHAELS KS et al.: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am. Psychiatry (1998) 155:1512–1520.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JH, FERNANDEZ HH: atypical antipsychotics in Parkinson sensitive populations. Ceriati: Psychiatry Neurol. (2002) 15(3):156–170.
   PubMedGoogle Scholar
• ••A good review article on the use ofatypical antipsychotic agents in Parkinsonian populations.
   Google Scholar
• FERNANDEZ HH, FRIEDMAN JH: The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs (1999) 11(6):467–483.
   Google Scholar
• BURKE WJ, PFEIFFER RF,MCCOMB RD: Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. Neuropsychiatry Clin. NeuroscL (1998) 10:227–229.
   PubMed Web of Science ®Google Scholar
• KATZ IR, JESTE DV, MINTZER JE, CLYDE C, NAPOLITANO J,BRECHER M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. .1 Psychiatry (1999) 60:107–115.
   Google Scholar
• CUMMINGS JL, STREET J,MASTERMAN D, CLARK WS: Efficacy of Olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement. Ceriatr. Cogn. Disord. (2002) 13:67–73.
   PubMed Web of Science ®Google Scholar
• WALKER Z, GRACE J, OVERSHOT R et al.: Olanzapine in dementia with Lewybodies: a clinical study. Int. J. Geriatr Psychiatry (1999) 14:459–466.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ HH,TRIESCHMANN ME, BURKE MA, JACQUES C, FRIEDMAN JH: Long-term quetiapine use for drug-induced psychosis among parkinsonian patients. Mov. Disord. (2003) 18(5):510–514.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ HH, TRIESCHMANN ME, BURKE MA, FRIEDMAN JH: Quetiapine for psychosis in Parkinson's disease versus dementia with Ley bodies. j. Clin. Psychiatry (2002) 63(6):513–515.
   PubMedGoogle Scholar
• NYTH AL, GOTTFRIES CG, LYBY K et al.: A controlled multicenter clinical study of citalopram and placebo in elderly depressed patient with and without concomitant dementia. Acta Psychiatr. Scand. (1992) 86:138–145.
   PubMed Web of Science ®Google Scholar
• POLLOCK BG, MULSANT BH, SWEET R et al: An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations.Geriatr Psychiatry (1997) 5:70–78.
   Google Scholar
• LAWLOR BA, RADCLIFFE H,MOLCHAN SE: A pilot placebo-controlled study of trazadone and buspirone in Alzheimer's disease. Int. Geriatr. Psychiatry (1994) 9:55–59.
   Web of Science ®Google Scholar
• SULTZER DL, GRAY KF, GUNAY I, BERISFORD MA, MAHLER ME: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Jim. I Geriatr. Psychiatry (1997) 5:60–69.
   PubMed Web of Science ®Google Scholar
• CANTILLON M, BRUNSWICK R, MOLINA D: Buspirone versus haloperidol: a double-blind trial for agitation in anursing home population with Alzheimer's disease. Am. Geriatr. Psychiatry (1996) 4:263–267.
   PubMedGoogle Scholar
• SAKAUYE KM, CAMP CJ, FORD PA: Effects of Buspirone on agitation associated with dementia. Am. I Geriatr. Psychiatry (1993) 1:82–84.
   PubMedGoogle Scholar
• FRIEDMAN JH, FERNANDEZ HH: Non-Motor Problems in Parkinson's disease. The Neurologist (2000) 6(1):18–27.
   Google Scholar
• PARKINSON STUDY GROUP: Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA (2000) 284:1931–1938.
   PubMed Web of Science ®Google Scholar
• RASCOL 0, BROOKS DJ,KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med (2000) 342:1484–1491.
   PubMed Web of Science ®Google Scholar
• ASHRAF W, PFEIFFER RE PARK F, LOF J, QUIGLEY EM: Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov. Disord. (1997) 12:946–951.
   PubMed Web of Science ®Google Scholar
• KORNHUBER J, WELLER M: Psychotogeneticity and N-methyl-D-aspartate receptor receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry (1997) 41:135–144.
   PubMed Web of Science ®Google Scholar
• RABEY JM, NISSIPEANU P,KORCZYN AD: Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural. Park. Dis. Dement. Sect. (1992) 4:277–282.
   PubMed Web of Science ®Google Scholar
• MERELLO M, NOUZEILLES MI, CAMMAROTA A, LEIGUARDA R: Effect of memantine on Parkinson's disease: a double-blind crossover randomized study. Clin. Neuropharmacol (1999) 22(5):273–276.
   PubMedGoogle Scholar
• WINBLAD B, PORITIS N: Memantine in severe dementia: results of the 9-M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine. hit. I Geriar. Psychiatry (1999) 14:135–146.
   PubMed Web of Science ®Google Scholar
• RUTHER E, GLASER A, BLEICH S, DEGNER D, WILTFANG J: A prospective study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry (2000) 33(3):103–108.
   PubMed Web of Science ®Google Scholar
• REISBERG B, DOODY R, STOFFLER, SCHMITT F, FERRIS S, MOBIUS HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl. J. Med. (2003) 348:1333-1341.Affiliation
   Google Scholar